NCT06196619

Brief Summary

The aim of this study is to evaluate the relationship between disease severity and subcutaneous tissue shearwave elastography findings with pain threshold and quality of life in patients diagnosed with lipedema.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 25, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 9, 2024

Completed
Last Updated

January 9, 2024

Status Verified

November 1, 2023

Enrollment Period

4 months

First QC Date

December 25, 2023

Last Update Submit

December 25, 2023

Conditions

Keywords

Shear Wave ElastographyPainLipedema

Outcome Measures

Primary Outcomes (4)

  • Subcutaneous elastic modulus with shear wave elastography (SWE) imaging of lower limbs

    Measurements using B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography (SWE) imaging of lower limbs at three anatomical levels.

    1 day

  • Visual analog scale(VAS)

    Pain levels were assessed using the visual analog scale(VAS)

    1 day

  • Algometric measurement

    Pain threshold through algometric measurement

    1 day

  • EQ-5D general quality of life scale.

    quality of life using the EQ-5D general quality of life scale.

    1 day

Study Arms (3)

Stage 1 lipedema patients

It is the stage where normal skin surface, enlarged subcutaneous fat tissue, and many small nodules are present upon palpation.

Diagnostic Test: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level

Stage 2 lipedema patients

It is the stage with rough skin surface, large nodules of palpable subcutaneous fat tissue

Diagnostic Test: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level

Stage 3 lipedema patients

It is the stage in which lobular deformation of the skin surface occurs with enlarged fatty tissue.

Diagnostic Test: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level

Interventions

Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.

Also known as: visual analog scale(VAS), pain threshold through algometric measurement, EQ-5D general quality of life scale.
Stage 1 lipedema patientsStage 2 lipedema patientsStage 3 lipedema patients

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study consist of female patients aged 18-70, diagnosed with lipedema

You may qualify if:

  • Female patients diagnosed with lipedema

You may not qualify if:

  • under 18 years of age,
  • Patients with edema of cardiac or nephrogenic origin, diabetes mellitus, thyroid dysfunction, patients with lymphedema or chronic venous insufficiency, oncology patients,
  • individuals with polyneuropathy, radiculopathy, or advanced degenerative diseases affecting the extremities within the last 6 months, based on clinical findings and medical history.
  • patients using antiepileptics and antidepressants,
  • individuals unable to cognitively tolerate participation in the study were also excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gulcan Ozturk

Istanbul, 34752, Turkey (Türkiye)

Location

Related Publications (3)

  • Clarke C, Kirby JN, Smidt T, Best T. Stages of lipoedema: experiences of physical and mental health and health care. Qual Life Res. 2023 Jan;32(1):127-137. doi: 10.1007/s11136-022-03216-w. Epub 2022 Aug 16.

    PMID: 35972618BACKGROUND
  • Ishaq M, Bandara N, Morgan S, Nowell C, Mehdi AM, Lyu R, McCarthy D, Anderson D, Creek DJ, Achen MG, Shayan R, Karnezis T. Key signaling networks are dysregulated in patients with the adipose tissue disorder, lipedema. Int J Obes (Lond). 2022 Mar;46(3):502-514. doi: 10.1038/s41366-021-01002-1. Epub 2021 Nov 11.

    PMID: 34764426BACKGROUND
  • Buso G, Depairon M, Tomson D, Raffoul W, Vettor R, Mazzolai L. Lipedema: A Call to Action! Obesity (Silver Spring). 2019 Oct;27(10):1567-1576. doi: 10.1002/oby.22597.

    PMID: 31544340BACKGROUND

MeSH Terms

Conditions

PainLipedema

Interventions

Visual Analog Scale

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsConnective Tissue DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosis

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 25, 2023

First Posted

January 9, 2024

Study Start

April 1, 2023

Primary Completion

August 1, 2023

Study Completion

November 1, 2023

Last Updated

January 9, 2024

Record last verified: 2023-11

Locations